Cartalax Peptide: What It Is and What the Research Shows
Cartalax peptide is AED (Ala-Glu-Asp), a three amino acid peptide bioregulator that a 2021 review lists for regulating cartilage and skin cells. Its studies are all in cells and animal tissue: in aging human stem cells, the short peptides raised IGF1 gene activity 3.5 to 5.6 fold.
Despite the name, no study we found tested AED on cartilage, joints or people. Below are the results that do exist, cell type by cell type, so you can see how far they are from a knee.
Sources: Peptide Regulation of Gene Expression: A Systematic Review (22 November 2021), Europe PMC PMC8619776: lists AED, Cartalax, with cartilage and skin cell regulation; Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides (June 2020), PubMed 32399807: IGF1 up 3.5 to 5.6 fold, NFkB
Short answer
- What is Cartalax?
- AED (Ala-Glu-Asp), a short peptide also coded T-31 in some papers.
- Was it tested on cartilage?
- No. The only skeletal study is a 2007 rat bone density study.
- Was it tested in people?
- No human trial was found on PubMed, Europe PMC or ClinicalTrials.gov.
Where does the name Cartalax come from?
The name sounds like cartilage, and a 2021 review does list AED, Cartalax, with the regulation of cartilage and skin cell functions. That listing names a research area, not a proven effect.
AED is made of alanine, glutamic acid and aspartic acid. In a 2015 kidney tissue paper it appears under the code T-31. It belongs to a group called peptide bioregulators. A 2026 review on peptides and ageing says the field first made active peptide mixes from animal tissues, then built short lab-made peptides aimed at one tissue type.
Two other short peptides from this kind of research have their own pages: epitalon and pinealon. They are different molecules, so their results do not apply to Cartalax.
Sources: Peptide Regulation of Gene Expression: A Systematic Review (22 November 2021), Europe PMC PMC8619776: lists AED, Cartalax, with cartilage and skin cell regulation; Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals (May 2015), PubMed 26033601: kidney tissue study, AED coded T-31; Peptide Regulation of Ageing: From Experiment to Practice (2026), PubMed 42839866: how peptide bioregulator research began
What did the Cartalax studies actually measure?
They measured cell growth, cell death, aging markers and gene activity, almost all in cells grown in a dish. Here is each result, with the cell type and the year.
- Aging human stem cells, 2020. IGF1 gene activity rose 3.5 to 5.6 fold when the short peptides were added. AED, KED and KE also raised activity of a gene called NFkB.
- Aging skin cells, 2016. AED and AEDG lowered a type of cell death that rises as the cultures age. All the peptides tested lowered the enzyme MMP-9 and raised Ki-67 and CD98hc, two markers that drop as cells age.
- Young and aged kidney cells, 2014. AED raised cell growth, lowered the aging markers p16, p21 and p53, and raised SIRT-6. The paper also reported that AED fits best in the minor groove of DNA.
- Kidney tissue from young and old animals, 2015. AED raised cell growth and lowered cell death, but less than a polypeptide complex did.
- Stem cells from tissue around the teeth, 2019. The paper reports that the nerve marker GAP43 rose with the full mix of peptides and with KED alone.
- Rats with induced bone loss, 2007. The study tested T-31 and a cartilage extract on bone mineral density. It did not test joints.
A 2013 review of clinical results for peptide bioregulators lists seven products tested in people: Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin and Retinalamin. Cartalax is not one of them.
Sources: Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides (June 2020), PubMed 32399807: IGF1 up 3.5 to 5.6 fold, NFkB; Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro (May 2016), PubMed 27259496: aging skin cells, cell death and MMP-9; Tripeptides slow down aging process in renal cell culture (2014), PubMed 25946838: kidney cell aging markers and DNA groove binding; Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals (May 2015), PubMed 26033601: kidney tissue study, AED coded T-31; Effect of short peptides on neuronal differentiation of stem cells (2019), PubMed 30791821: stem cells from tissue around the teeth, nerve marker GAP43; Effect of peptide regulators on the structural and functional status of bone tissue in ageing rats (2007), PubMed 18306703: rat bone density study of T-31; Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results (2013), PubMed 24003726: seven products tested in people, Cartalax not among them
How is Cartalax supposed to work?
The research idea is that it switches genes on or off by reaching DNA. A 2021 systematic review says short peptides of 2 to 7 amino acids can enter the cell nucleus and bind DNA and the proteins DNA wraps around.
That idea has not been shown in a living body. The gene changes listed above were seen in dishes, and a gene change in a dish is not a health effect.
Can Cartalax help knee cartilage or arthritis?
No one knows, because no study has tested AED on cartilage cells, animal joints or human knees. The 2007 rat study measured bone density, which is not cartilage repair.
A 2023 review on peptides that steer stem cells toward cartilage says safe and effective ways to treat osteoarthritis have not yet been discovered. It names SK2.1, BMP and B2A among the most promising peptides. AED is not on its list.
For research peptides studied for joints, see best peptides for arthritis.
Sources: Effect of peptide regulators on the structural and functional status of bone tissue in ageing rats (2007), PubMed 18306703: rat bone density study of T-31; Peptide Regulation of Chondrogenic Stem Cell Differentiation (8 May 2023), PubMed 37176122: cartilage peptide review, no proven osteoarthritis treatment
Is Cartalax safe?
Its safety has not been studied. We found no human or animal safety study and no published human dose.
The US FDA lists bulk substances that may pose safety risks in compounding, and Cartalax is not named there. On the same page, the FDA says it has not identified safety-related information for epitalon, a different short peptide. In the 2020 stem cell study, AED raised activity of a gene called NFkB. What that means for a person is unknown.
Disclaimer: this page is education about published research, not medical advice. Decisions about any compound belong with a licensed clinician.
Sources: US FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026): epitalon entry; Cartalax not listed; Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides (June 2020), PubMed 32399807: IGF1 up 3.5 to 5.6 fold, NFkB
Common Questions
How does Cartalax work?+
Nobody has shown how it works in a living person. A 2021 systematic review says short peptides of 2 to 7 amino acids can enter the cell nucleus and bind DNA. A 2020 stem cell study found AED raised activity of a gene called NFkB. These are lab findings, not proof of what happens in the body.
Does Cartalax really work?+
There is no human evidence that it does. Every study found was done in cells in a dish, in animal kidney tissue in a dish, or in one rat bone study. A 2013 review of clinical studies of peptide bioregulators lists seven products tested in people, and Cartalax is not one of them.
What are the side effects of Cartalax?+
No one knows. No human or animal safety study of Cartalax was found, so there is no list of side effects. The FDA compounding safety page does not name it either.
Can peptides heal knee cartilage?+
Not on current evidence for Cartalax. No study found tested AED on cartilage cells, animal joints or human knees. A 2023 review of peptides for cartilage cell growth names other peptides, such as SK2.1, BMP and B2A, as the most promising.
Are peptides an effective treatment for arthritis?+
Not proven. A 2023 review on peptides and cartilage stem cells says safe and effective ways to treat osteoarthritis have not yet been discovered. No arthritis study of Cartalax was found.
Is peptide safe for you?+
It depends on the peptide, and for Cartalax it has not been studied. For epitalon, a different short peptide, the FDA says it has not identified safety-related information and that compounded forms may pose a risk of immune reactions for certain routes.
What is the most powerful peptide for fat loss?+
Cartalax is not a fat loss peptide. No study found links AED to fat loss. Our guide to peptides for muscle growth and fat loss covers that question.
What is Cartalax?+
Cartalax is a name used for AED, a short peptide of three amino acids: alanine, glutamic acid and aspartic acid (Ala-Glu-Asp). It is a research compound with no human trials and no published human dose.
Asking about fat loss? See peptides for muscle growth and fat loss.
Sources: Peptide Regulation of Gene Expression: A Systematic Review (22 November 2021), Europe PMC PMC8619776: lists AED, Cartalax, with cartilage and skin cell regulation; Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides (June 2020), PubMed 32399807: IGF1 up 3.5 to 5.6 fold, NFkB; Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results (2013), PubMed 24003726: seven products tested in people, Cartalax not among them; Peptide Regulation of Chondrogenic Stem Cell Differentiation (8 May 2023), PubMed 37176122: cartilage peptide review, no proven osteoarthritis treatment; US FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026): epitalon entry; Cartalax not listed
Related reading
This guide is for educational purposes only and is not medical advice. It describes what published cell and animal research reports about AED (Cartalax). It is not an endorsement or an instruction to use any compound. Cartalax is a research compound that is not approved for human use. Talk to a qualified healthcare professional before making any decision about your health.